Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
10.55
+0.59 (5.92%)
At close: Nov 28, 2025, 4:00 PM EST
10.38
-0.17 (-1.61%)
After-hours: Nov 28, 2025, 4:00 PM EST
Kazia Therapeutics Employees
Kazia Therapeutics had 6 employees as of June 30, 2025. The number of employees decreased by 1 or -11.76% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-11.76%
Revenue / Employee
$199,851
Profits / Employee
-$2,262,069
Market Cap
19.36M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 6 | -1 | -11.76% |
| Jun 30, 2024 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
KZIA News
- 10 days ago - Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - PRNewsWire
- 4 weeks ago - Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - PRNewsWire
- 7 weeks ago - Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program - PRNewsWire
- 2 months ago - Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen - PRNewsWire
- 2 months ago - Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG - PRNewsWire
- 2 months ago - Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy - PRNewsWire
- 4 months ago - Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market - PRNewsWire
- 5 months ago - Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial - PRNewsWire